AIM
ACAD icon

Advyzon Investment Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Advyzon Investment Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,612
Closed -$310K – 676
2025
Q4 		$310K Buy
11,612
+798
+7% +$19.1K 0.04% 436
2025
Q3 		$231K Buy
10,814
+1,270
+13% +$30K 0.04% 392
2025
Q2 		$206K Buy
+9,544
New +$177K 0.05% 362

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Advyzon Investment Management's ACAD Position: Q1 2026 in Review

Advyzon Investment Management sold out of Acadia Pharmaceuticals (ACAD) in Q1 2026, closing a stake of 11,612 shares — an estimated $310K sold.

Advyzon Investment Management first reported a position in ACAD in Q2 2025 and held it in 3 quarters. The position peaked at $310K in Q4 2025. 343 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Advyzon Investment Management reported no remaining Acadia Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Advyzon Investment Management sold 11,612 Acadia Pharmaceuticals shares in Q1 2026, an estimated $310K.
  • Advyzon Investment Management first reported a position in Acadia Pharmaceuticals in Q2 2025 and held it in 3 quarters.
  • Advyzon Investment Management's Acadia Pharmaceuticals position peaked at $310K in Q4 2025.
  • 343 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Advyzon Investment Management's 13F filing for Q1 2026, filed 12 May 2026.